CVS Health Corp (CVS) Holdings Decreased by Stoneridge Investment Partners LLC

Stoneridge Investment Partners LLC decreased its stake in shares of CVS Health Corp (NYSE:CVS) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,282 shares of the pharmacy operator’s stock after selling 1,151 shares during the quarter. Stoneridge Investment Partners LLC’s holdings in CVS Health were worth $2,630,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CVS. Fieldpoint Private Securities LLC increased its holdings in shares of CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 1,000 shares during the last quarter. Wealthcare Advisory Partners LLC increased its holdings in shares of CVS Health by 330.3% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after acquiring an additional 991 shares during the last quarter. Arcadia Investment Management Corp MI increased its holdings in shares of CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after acquiring an additional 726 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of CVS Health during the 2nd quarter worth approximately $119,000. Finally, Cerebellum GP LLC acquired a new position in shares of CVS Health during the 4th quarter worth approximately $130,000. 83.96% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of CVS stock opened at $60.86 on Friday. The firm has a market capitalization of $62,687.93, a price-to-earnings ratio of 9.41, a PEG ratio of 1.01 and a beta of 1.03. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59. CVS Health Corp has a 1 year low of $60.78 and a 1 year high of $84.00.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. The firm had revenue of $48.39 billion during the quarter, compared to the consensus estimate of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.71 EPS. sell-side analysts anticipate that CVS Health Corp will post 6.37 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Stockholders of record on Monday, April 23rd will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, April 20th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.29%. CVS Health’s payout ratio is 30.91%.

In other news, EVP Helena Foulkes sold 19,965 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the completion of the sale, the executive vice president now directly owns 65,072 shares in the company, valued at approximately $4,622,714.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.61% of the company’s stock.

A number of research analysts recently weighed in on the company. Needham & Company LLC raised CVS Health from a “buy” rating to a “strong-buy” rating and boosted their target price for the stock from $88.00 to $100.00 in a report on Tuesday, January 30th. Mizuho set a $95.00 target price on CVS Health and gave the stock a “buy” rating in a report on Wednesday, January 24th. Cowen reissued an “outperform” rating and set a $99.00 target price (up from $81.00) on shares of CVS Health in a report on Thursday, January 18th. Vetr lowered CVS Health from a “hold” rating to a “sell” rating and set a $76.66 target price on the stock. in a report on Tuesday, January 16th. Finally, ValuEngine downgraded CVS Health from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $87.03.

ILLEGAL ACTIVITY NOTICE: “CVS Health Corp (CVS) Holdings Decreased by Stoneridge Investment Partners LLC” was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3296015/cvs-health-corp-cvs-holdings-decreased-by-stoneridge-investment-partners-llc.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Apricus Biosciences  Hits New 12-Month High and Low at $0.25
Apricus Biosciences Hits New 12-Month High and Low at $0.25
Hain Celestial Group  Sets New 12-Month High and Low at $29.83
Hain Celestial Group Sets New 12-Month High and Low at $29.83
EnteroMedics  Sets New 52-Week High and Low at $0.60
EnteroMedics Sets New 52-Week High and Low at $0.60
First Internet Bancorp’s  Buy Rating Reiterated at Maxim Group
First Internet Bancorp’s Buy Rating Reiterated at Maxim Group
Show  Reaches Market Cap of $0.00
Show Reaches Market Cap of $0.00
PayCoin  Price Tops $0.0344 on Major Exchanges
PayCoin Price Tops $0.0344 on Major Exchanges


© 2006-2018 Ticker Report. Google+.